What does Vedolizumab biologic therapy involve?

Vedolizumab is a gut-selective integrin blocker administered as an intravenous infusion over approximately 30 minutes. It works by binding to α4β7 integrin on lymphocytes, preventing them from migrating into the gastrointestinal tract and reducing inflammation in moderate-to-severe ulcerative colitis. The standard regimen includes an initial loading phase (doses at weeks 0, 2, and 6), followed by maintenance infusions every 8 weeks. The procedure is performed in an outpatient setting, meaning you can return home shortly after each session.